Insights from GMFH World Summit 2026 on Diet and Gut Microbiome Manipulation

Lawrence David, PhD, from Duke University, introduced FoodSeq, a method utilizing DNA sequencing technology to assess diet through degraded food DNA in human stool. His case studies suggest that DNA metabarcoding correlates with dietary diversity and quality as evaluated by traditional self-report methods. Limitations of this approach include challenges in detecting certain food constituents in feces and distinguishing between food types with the same source species.

Ciarán G. Forde, PhD, from Wageningen University, discussed the RESTRUCTURE trial, which found that consuming over 90% of daily calories from ultra-processed foods for 14 days did not significantly impact gut health markers or microbiota composition in healthy individuals. However, caution is advised as the study's duration may not be sufficient to observe meaningful changes. Findings from the ADDapt trial indicated that restricting emulsifier intake for 8 weeks improved symptoms in Crohn’s disease patients, highlighting differences in gut responses to ultra-processed foods between healthy individuals and clinical populations.

Heather Armstrong, PhD, from the University of Manitoba, stressed the need for personalized dietary fiber guidelines, especially for patients with inflammatory bowel disease (IBD). She presented evidence that not all fibers are beneficial and that certain types, like b-fructans, may provoke inflammation in some individuals. Her research aims to determine which carbohydrates are safe or harmful based on fecal microbiota signatures.

Jens Walter, PhD, from University College Cork, showcased the potential benefits of a high-fiber, predominantly plant-based diet on gut microbiome and cardiometabolic risk. His findings suggested that these dietary changes positively impacted weight and cholesterol levels. Additionally, Walter noted that high-fiber diets' benefits were often not replicated in interventions involving isolated fibers.

Eran Segal, PhD, from the Weizmann Institute, presented research on the variability of individual responses to foods, emphasizing the necessity for personalized nutrition based on individual microbiome and metabolomic profiles. Nicolata Segata, PhD, from the University of Trento, discussed how microbiome diversity can influence dietary responses, and findings from the PROSPECT study indicated that stool metagenomics could effectively screen for colorectal cancer.

Max Nieuwdorp, PhD, from the Academic Medical Center in Amsterdam, detailed the relationship between small intestinal lactic acid bacteria and ethanol production in those with metabolic dysfunction. He also evaluated the role of fecal microbiota transplants (FMT) in obesity treatment. Recent trials have shown high success rates for specific FMT based on donor strains.

Nicolas Benech, MD, PhD, presented promising results from the LIVEDIFF trial, showing that a strain of Faecalibacterium prausnitzii could safely prevent Clostridioides difficile recurrence in high-risk patients. Purna C. Kashyap, MBBS, AGAF, from the Mayo Clinic, emphasized new connections between gut microbiome and IBS symptoms, advocating for treatment approaches that target underlying physiological mechanisms.

The summit concluded with discussions on the role of the gut microbiome in enhancing cancer therapy. Gianluca Ianiro, MD, PhD, revealed findings from the TACITO trial highlighting the successful use of FMT in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitors. The potential for gut microbiome therapies was further explored by Lisa Derosa, MD, PhD, showcasing Akermansia muciniphila as a predictive marker for immunotherapy effectiveness.

The 15th GMFH World Summit is scheduled for 2028 in Bordeaux, France.